TY  - JOUR
AU  - Brusniak, Katharina
AU  - Feisst, Manuel
AU  - Sebesteny, Linda
AU  - Hartkopf, Andreas
AU  - Graf, Joachim
AU  - Engler, Tobias
AU  - Schneeweiss, Andreas
AU  - Wallwiener, Markus
AU  - Deutsch, Thomas Maximilian
PY  - 2021
DA  - 2021/10/12
TI  - Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study
JO  - JMIR Cancer
SP  - e25776
VL  - 7
IS  - 4
KW  - eHealth
KW  - breast cancer
KW  - health-related quality of life
KW  - quality of life
KW  - time to deterioration
KW  - EQ-VAS
KW  - EQ-5D-5L
KW  - EORTC QLQ-C30
AB  - Background: Health-related quality of life (HRQoL) is used to evaluate the treatment of metastatic breast cancer. In a long-term therapy setting, HRQoL can be used as an important benchmark for treatment success. With the help of digital apps, HRQoL monitoring can be extended to more remote areas and be administered on a more frequent basis. Objective: This study aims to evaluate 3 common HRQoL questionnaires in metastasized breast cancer in terms of TTD in a digital, web-based setting. We further aim to examine the development of the HRQoL in different systemic treatment groups in each of these evaluation instruments. Methods: A total of 192 patients with metastatic breast cancer were analyzed in this bicentric prospective online cohort study at two German university hospitals. Patients completed questionnaires on HRQoL (EuroQol Visual Analog Scale [EQ-VAS], EuroQol 5 Dimension 5 Level [EQ-5D-5L], European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 item [EORTC QLQ-C30]) via an online platform over a 6-month period. Treatment schedules and medical history were retrieved from medical records. Unadjusted Cox regression analysis on treatment-related factors was performed. We conducted subgroup analyses in regard to TTD events between different treatments. Results: The EQ-VAS showed a higher rate of deterioration after 8 weeks (84/179, 46.9%) than the EQ-5D-5L (47/163, 28.8%) and EORTC QLQ-C30 (65/176, 36.9%). Unadjusted Cox regression revealed significant connections between known metastases in the liver (P=.03, HR 1.64, 95% CI 1.06-2.52) and pleura (P=.04, HR 0.42, 95% CI 0.18-0.96) in the EQ-VAS. Significant relations between EQ-VAS events and single EQ-5D-5L items and the EQ-5D-5L summary score were demonstrated. All treatment groups significantly differed from the CDK4/6 inhibition subgroup in the EQ-VAS. Conclusions: Compared to the EQ-5D-5L and QLQ-C30, the EQ-VAS showed a higher rate of deterioration after 8 weeks. Significant connections to certain metastatic locations were only detected in the EQ-VAS. The EQ-VAS is capable of reflecting the distinctive HRQoL profiles of different systemic treatments as well as the different aspects of HRQoL presented in the EQ-5D-5L. TTD with the EQ-VAS is an adequate mean of examining longitudinal development of HRQoL among breast cancer patients. 
SN  - 2369-1999
UR  - https://cancer.jmir.org/2021/4/e25776
UR  - https://doi.org/10.2196/25776
UR  - http://www.ncbi.nlm.nih.gov/pubmed/34636732
DO  - 10.2196/25776
ID  - info:doi/10.2196/25776
ER  -